|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:abbreviation
|
gptkb:Sinopharm
|
|
gptkbp:CEO
|
gptkb:Liu_Yong
|
|
gptkbp:country
|
gptkb:China
|
|
gptkbp:founded
|
1998
|
|
gptkbp:headquarters_location
|
gptkb:Beijing
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sinopharm Group
|
|
gptkbp:industry
|
healthcare
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Liu_Yong
gptkb:Yu_Qingming
|
|
gptkbp:listedOn
|
gptkb:Fortune_Global_500
|
|
gptkbp:notableProduct
|
gptkb:Sinopharm_BIBP_COVID-19_vaccine
gptkb:Sinopharm_WIBP_COVID-19_vaccine
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:parentOrganization
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:products
|
pharmaceuticals
medical devices
vaccines
|
|
gptkbp:revenue
|
over 500 billion RMB (2022)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Hong_Kong_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:1099.HK
|
|
gptkbp:subsidiary
|
gptkb:China_National_Medicines_Corporation
gptkb:Sinopharm_CNMC
gptkb:Sinopharm_Holding_Guoda_Drugstore
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
http://www.sinopharm.com/
|
|
gptkbp:bfsParent
|
gptkb:Shanghai_Stock_Exchange
|
|
gptkbp:bfsLayer
|
5
|